[Bipressil® : first single-pill combination of bisoprolol and perindopril arginine]

Area of Science:

• Cardiology
• Pharmacology

Background:

• Cardiovascular diseases like hypertension, coronary artery disease, and heart failure are leading causes of mortality.
• Non-adherence to prescribed treatments is a significant factor contributing to suboptimal outcomes in these patients.
• Pharmacological interventions are crucial for preventing cardiovascular events.

Purpose of the Study:

• To introduce the first dual-pill combination of a cardioselective beta-blocker and an angiotensin-convertase enzyme inhibitor.
• To highlight the potential of fixed-dose combinations to improve treatment compliance and efficacy.

Main Methods:

• This article describes the characteristics of a novel pharmaceutical formulation.
• The formulation combines bisoprolol, a cardioselective beta-blocker, with perindopril arginine, an angiotensin-convertase enzyme inhibitor.

Main Results:

• The development of a single-pill dual association addresses the challenge of treatment non-adherence.
• This combination aims to enhance patient compliance and, consequently, therapeutic effectiveness.

Conclusions:

• Fixed-dose combination therapy, such as bisoprolol and perindopril arginine, offers a promising strategy to improve cardiovascular event prevention.
• Enhanced treatment adherence through single-pill formulations can lead to better patient outcomes in managing chronic cardiovascular conditions.